ADMA Biologics Shares Jump On Increased Manufacturing Capacity For Intravenous Immune Globulin

by Vandana Singh, Benzinga Editor

April 28, 2021 8:41 AM | 1 min read |

The FDA has approved ADMA Biologics Inc's ADMA expanded manufacturing process, enabling fractionation and purification of a 4,400-liter plasma pool to manufacture Intravenous Immune Globulin (IVIG).
The 4,400-liter IVIG plasma pool scale for BIVIGAM will allow ADMA to expand its manufacturing plant's total processing capacity from 400,000 liters to an anticipated peak throughput of up to 600,000 liters.
Due to the expanded plasma pool production scale, the company now sees peak revenues over $300 million and gross margin expansion beginning potentially in the second half of 2021 and accelerating throughout 2022.
With this approval, ADMA will now offer BIVIGAM in two vial sizes, both the 50 mL and 100 mL configurations.
Price Action: ADMA shares are 18.4% at $2.25 in the premarket session on the last check Wednesday.

Posted In: News Penny Stocks Health Care General Briefs

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.